Encephalomyelitis - Pipeline Review, H2 2017

Publisher Name :
Date: 16-Aug-2017
No. of pages: 62
Inquire Before Buying

Encephalomyelitis - Pipeline Review, H2 2017

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Encephalomyelitis - Pipeline Review, H2 2017, provides an overview of the Encephalomyelitis (Central Nervous System) pipeline landscape.

Encephalomyelitis is an inflammation of the brain and spinal cord. Encephalomyelitis can be caused by a variety of conditions that lead to irritation of the brain and spinal cord. Among the common causes of encephalomyelitis are viruses which infect the nervous tissues. Signs and symptoms include neck stiffness, headache, and fever. Treatment includes antibiotics and corticosteroids.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Encephalomyelitis - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Encephalomyelitis (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Encephalomyelitis (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Encephalomyelitis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase II, IND/CTA Filed and Preclinical stages are 1, 3, 1 and 5 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 5 molecules, respectively.

Encephalomyelitis (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Encephalomyelitis (Central Nervous System).

- The pipeline guide reviews pipeline therapeutics for Encephalomyelitis (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.

- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

- The pipeline guide reviews key companies involved in Encephalomyelitis (Central Nervous System) therapeutics and enlists all their major and minor projects.

- The pipeline guide evaluates Encephalomyelitis (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

- The pipeline guide reviews latest news related to pipeline therapeutics for Encephalomyelitis (Central Nervous System)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

- Find and recognize significant and varied types of therapeutics under development for Encephalomyelitis (Central Nervous System).

- Classify potential new clients or partners in the target demographic.

- Develop tactical initiatives by understanding the focus areas of leading companies.

- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

- Formulate corrective measures for pipeline projects by understanding Encephalomyelitis (Central Nervous System) pipeline depth and focus of Indication therapeutics.

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Encephalomyelitis - Pipeline Review, H2 2017

Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Encephalomyelitis - Overview
Encephalomyelitis - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Encephalomyelitis - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Encephalomyelitis - Companies Involved in Therapeutics Development
Aurigene Discovery Technologies Ltd
Biovista Inc
Grifols SA
Hemispherx Biopharma Inc
Johnson & Johnson
K-Pax Pharmaceuticals Inc
Momenta Pharmaceuticals Inc
Philogen SpA
Encephalomyelitis - Drug Profiles
alpha-1 proteinase inhibitor (human) - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
alpha-1 proteinase inhibitor (recombinant) - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
FR-104 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
JM-4 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
KPAX-002 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
M-254 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Preimplantation Factor - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PSA-20 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
rintatolimod - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule for Chronic Fatigue Syndrome - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Activate NF-E2 Related Factor 2 for Central Nervous System, Metabolic Disorders, Cardiovascular and Ophthalmology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Antagonize ROR-Gamma for Inflammation and Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
tetravil - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
thymulin - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
WEHI-345 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Encephalomyelitis - Dormant Projects
Encephalomyelitis - Product Development Milestones
Featured News & Press Releases
May 31, 2017: Hemispherx Biopharma Enhances Ampligen Manufacturing and Scientific Capabilities
May 31, 2017: Hemispherx Biopharma Repurposes Ampligen in Immuno-Oncology
Oct 31, 2016: Hemispherx Biopharma Announces Identification of High Responder Patient Subgroup from Ampligen Phase III Trial in Patients with CFS/ME
Aug 23, 2016: Hemispherx Biopharma Announces Major Breakthrough: Approval for Commercial Sale of Rintatolimod (U.S. Tradename: Ampligen) to Treat Severe Cases of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) in the Argentine Republic
Jul 27, 2016: Hemispherx Biopharma Reaches Agreement with Avrio Biopharmaceuticals for the Accelerated Production of Ampligen
Jun 07, 2016: Hemispherx Biopharma: Dr. William M. Mitchell Publishes Article Titled, "Efficacy of Rintatolimod in the Treatment of Chronic Fatigue Syndrome/Myalgic Encephalomyelitis (CFS/ME)" in Expert Review of Clinical Pharmacology
Mar 10, 2016: Hemispherx Biopharma Reviews Ampligen Data with National Institute of Neurological Disorders and Stroke
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products under Development for Encephalomyelitis, H2 2017
Number of Products under Development by Companies, H2 2017
Number of Products under Development by Universities/Institutes, H2 2017
Products under Development by Companies, H2 2017
Products under Development by Universities/Institutes, H2 2017
Number of Products by Stage and Target, H2 2017
Number of Products by Stage and Mechanism of Action, H2 2017
Number of Products by Stage and Route of Administration, H2 2017
Number of Products by Stage and Molecule Type, H2 2017
Encephalomyelitis - Pipeline by Aurigene Discovery Technologies Ltd, H2 2017
Encephalomyelitis - Pipeline by Biovista Inc, H2 2017
Encephalomyelitis - Pipeline by Grifols SA, H2 2017
Encephalomyelitis - Pipeline by Hemispherx Biopharma Inc, H2 2017
Encephalomyelitis - Pipeline by Johnson & Johnson, H2 2017
Encephalomyelitis - Pipeline by K-Pax Pharmaceuticals Inc, H2 2017
Encephalomyelitis - Pipeline by Momenta Pharmaceuticals Inc, H2 2017
Encephalomyelitis - Pipeline by Philogen SpA, H2 2017
Encephalomyelitis - Dormant Projects, H2 2017
Encephalomyelitis - Dormant Projects, H2 2017 (Contd..1), H2 2017

List of Figures
Number of Products under Development for Encephalomyelitis, H2 2017
Number of Products under Development by Companies, H2 2017
Number of Products by Top 10 Targets, H2 2017
Number of Products by Stage and Top 10 Targets, H2 2017
Number of Products by Top 10 Mechanism of Actions, H2 2017
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2017
Number of Products by Routes of Administration, H2 2017
Number of Products by Stage and Routes of Administration, H2 2017
Number of Products by Molecule Types, H2 2017
Number of Products by Stage and Molecule Types, H2 2017
  • Bipolar Disorder (Manic Depression) - Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2017
    Published: 01-Nov-2017        Price: US 2000 Onwards        Pages: 60
    DelveInsight's, Bipolar Disorder (Manic Depression) - Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2017" report provides comprehensive insights about marketed and Phase III products for the Bipolar Disorder (Manic Depression). The report includes information of marketed products including their product description, patent details, forecasted sales till 2020 & API manufacturer details by country. It also provides a comprehensive understanding of the emerging Phase III therapi......
  • Lennox Gastaut Syndrome -Epidemiology Forecast to 2025
    Published: 01-Nov-2017        Price: US 2750 Onwards        Pages: 40
    DelveInsight "Lennox Gastaut Syndrome - Epidemiology Forecast To 2025" provides an overview of the epidemiology trends of Lennox Gastaut Syndrome in seven major markets (US, France, Germany, Italy, Spain, UK and Japan). It includes 10 years epidemiology historical and forecasted data of Lennox Gastaut Syndrome prevalent or incident cases segmented by age, sex and subpopulations. The Report also discusses the prevailing risk factors, disease burden with special emphasis on the unmet medical need ......
  • Spasticity - Market Insights, Epidemiology and Market Forecast - 2025
    Published: 01-Nov-2017        Price: US 5750 Onwards        Pages: 70
    DelveInsight's "Spasticity - Market Insights, Epidemiology and Market Forecast - 2025" report provides an overview of the disease and in depth research related to Spasticity for the 7MM (United States, Germany, France, Italy, Spain and UK) for the study period undertaken from 2015-2025. This report provides understanding of the patients affected, diagnosed patterns, treatment trends, unmet medical needs and current developments for Spasticity . It enables understanding of the historical and fore......
  • Migraine -Epidemiology Forecast to 2025
    Published: 01-Nov-2017        Price: US 2750 Onwards        Pages: 40
    DelveInsight "Migraine - Epidemiology Forecast To 2025" provides an overview of the epidemiology trends of Migraine in seven major markets (US, France, Germany, Italy, Spain, UK and Japan). It includes 10 years epidemiology historical and forecasted data of Migraine prevalent or incident cases segmented by age, sex and subpopulations. The Report also discusses the prevailing risk factors, disease burden with special emphasis on the unmet medical need associated with the Migraine . The report ......
  • Lennox Gastaut Syndrome - Market Insights, Epidemiology and Market Forecast - 2025
    Published: 01-Nov-2017        Price: US 5750 Onwards        Pages: 70
    DelveInsight's "Lennox Gastaut Syndrome - Market Insights, Epidemiology and Market Forecast - Market Insights, Epidemiology and Market Forecast - 2025" report provides an overview of the disease and in depth research related to Lennox Gastaut Syndrome - Market Insights, Epidemiology and Market Forecast for the 7MM (United States, Germany, France, Italy, Spain and UK) for the study period undertaken from 2015-2025. This report provides understanding of the patients affected, diagno......
  • Tardive Dyskinesia - Market Insights, Epidemiology and Market Forecast - 2025
    Published: 01-Nov-2017        Price: US 5750 Onwards        Pages: 70
    DelveInsight's "Tardive Dyskinesia - Market Insights, Epidemiology and Market Forecast - 2025" report provides an overview of the disease and in depth research related to Tardive Dyskinesia for the 7MM (United States, Germany, France, Italy, Spain and UK) for the study period undertaken from 2015-2025. This report provides understanding of the patients affected, diagnosed patterns, treatment trends, unmet medical needs and current developments for Tardive Dyskinesia . It enables understanding of......
  • Neuropathic Pain -Epidemiology Forecast to 2025
    Published: 01-Nov-2017        Price: US 2750 Onwards        Pages: 40
    DelveInsight "Neuropathic Pain - Epidemiology Forecast To 2025" provides an overview of the epidemiology trends of Neuropathic Pain in seven major markets (US, France, Germany, Italy, Spain, UK and Japan). It includes 10 years epidemiology historical and forecasted data of Neuropathic Pain prevalent or incident cases segmented by age, sex and subpopulations. The Report also discusses the prevailing risk factors, disease burden with special emphasis on the unmet medical need associated with th......
  • Narcolepsy - Market Insights, Epidemiology and Market Forecast-2023
    Published: 01-Nov-2017        Price: US 4950 Onwards        Pages: 99
    DelveInsight's "Narcolepsy - Market Insights, Epidemiology and Market Forecast-2023" Report provides an overview of the disease and global market size of the Narcolepsy for the 7MM (United States, EU5 (France, Germany, Italy, Spain and UK) and Japan. It also includes global historical and forecasted epidemiological data for the prevalent, diagnosed and treatable cases of Narcolepsy from 2013-2023. Narcolepsy is a chronic neurological / brain disorder which involves poor control of sleep a......
  • Obsessive-Compulsive Disorder -Epidemiology Forecast to 2025
    Published: 01-Nov-2017        Price: US 2750 Onwards        Pages: 40
    DelveInsight "Obsessive-Compulsive Disorder - Epidemiology Forecast To 2025" provides an overview of the epidemiology trends of Obsessive-Compulsive Disorder in seven major markets (US, France, Germany, Italy, Spain, UK and Japan). It includes 10 years epidemiology historical and forecasted data of Obsessive-Compulsive Disorder prevalent or incident cases segmented by age, sex and subpopulations. The Report also discusses the prevailing risk factors, disease burden with special emphasis on the u......
  • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - sales@rnrmarketresearch.com / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs